- Persistent severe hypertriglyceridemia is associated with recurrent acute pancreatitis (AP) even below the chylomicronemia threshold of 880 mg/dL, according to the investigators.
- This analysis pooled 757 adults with triglycerides of at least 500 mg/dL from the phase 3 SHASTA-3 and SHASTA-4 trials, randomized 2:1 to plozasiran 25 mg or placebo every 3 months.
- The 1-year absolute risk reduction (ARR) in AP events was 4.1% overall, 4.9% with triglycerides of at least 880 mg/dL, and 3.8% with triglycerides of 500 to less than 880 mg/dL.
- Among patients with prior AP, the ARR was 33.8%, with a number needed to treat of about 3.
In a pooled analysis of the phase 3 SHASTA-3 and SHASTA-4 trials, plozasiran reduced the 1-year absolute rate of acute pancreatitis (AP) events by 4.1% overall. Among patients with prior AP, the absolute reduction was 33.8%. Christie Ballantyne, MD (Baylor College of Medicine, Houston, TX), presented the analysis at the American Heart Association (AHA) Scientific Sessions on November 7, 2026. The results have not yet been published in a peer-reviewed journal.
AP prevention in hypertriglyceridemia has focused on patients with chylomicronemia, the investigators said. They noted that persistent severe hypertriglyceridemia (sHTG) despite conventional treatment is associated with recurrent AP even below the chylomicronemia threshold of 880 mg/dL. Plozasiran (Redemplo; Arrowhead Pharmaceuticals), an siRNA that silences APOC3, is approved in the United States for familial chylomicronemia syndrome. In SHASTA-3 and SHASTA-4, it reduced triglycerides by about 80% and AP risk by about 80%. The main results were presented at the European Society of Cardiology Congress in August 2026 and published in the New England Journal of Medicine.
Across the two trials (NCT06347003 and NCT06347016), 757 adults with sHTG, defined as triglycerides of at least 500 mg/dL, were randomized 2:1 to plozasiran 25 mg or placebo, given subcutaneously every 3 months. The investigators calculated 1-year ARRs and numbers needed to treat (NNT) for AP event rates overall and in subgroups defined by baseline triglycerides and prior AP. Arrowhead, which sponsored both trials, defines prior AP as AP within 5 years before screening. Safety was assessed through month 15.
Overall, the ARR was 4.1% (NNT about 24). It was 4.9% (NNT about 20) in patients with baseline triglycerides of at least 880 mg/dL and 3.8% (event-based NNT 27) in those with levels of 500 to less than 880 mg/dL. Among patients with prior AP, the ARR was 33.8% (NNT about 3). In the patients with prior AP, the ARR was 29.4% with triglycerides of at least 880 mg/dL and 36.4% with triglycerides of 500 to less than 880 mg/dL. Arrowhead reported no AP events among 35 plozasiran-treated patients with prior AP and triglycerides of at least 880 mg/dL, compared with five events among 17 on placebo. Reductions in APOC3 and triglycerides were consistent across demographic and clinical subgroups.
Treatment-emergent adverse events occurred in 73% of both groups and led to discontinuation in 1.2%. The investigators reported no treatment-related thrombocytopenia or hypersensitivity events, no clinically meaningful worsening of hemoglobin A1c over time, no clinically meaningful aminotransferase elevations, and no significant increase in hepatic fat. Arrowhead reported worsening glycemic control as an adverse event in 14% of patients on plozasiran and 8.7% on placebo, and three deaths in the plozasiran group that were judged unrelated to treatment.
For comparison, olezarsen, an antisense oligonucleotide against APOC3, was tested in 1,061 patients with sHTG in the CORE-TIMI 72a and CORE2-TIMI 72b trials (Marston et al., New England Journal of Medicine, 2026). AP incidence was lower with olezarsen than with placebo (rate ratio 0.15; 95% CI 0.05 to 0.40; P<0.001). The 1-year NNT was 20 overall and 4 among patients with both prior pancreatitis and baseline triglycerides ≥880 mg/dL. The US Food and Drug Administration approved olezarsen for sHTG in June 2026.
The investigators concluded that the findings support a risk-based approach to AP prevention that considers both persistent sHTG and history of AP. Arrowhead has said it plans to file a supplemental new drug application for sHTG by the end of 2026.
